Psychiatric Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Adolescents With Obesity
- Design
- Retrospective cohort · Unknown outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Participants had obesity/overweight without diabetes (age/BMI not reported in abstract); effects may be mediated by weight loss.
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Study tier 3[Auto] Observational design; confounding by indication and healthy-user effects cannot be excluded (auto-provisional).
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 20, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; quoted from abstract conclusions] Among adolescents with obesity, incretin-based therapy was not associated with increased psychiatric risk and was associated with lower risks of suicide-related events, suicidal ideation, and anxiety compared with lifestyle intervention. Although a lower risk was observed compared with lifestyle intervention, this finding should be interpreted cautiously given potential selection bias and the lack of a significant difference in the active-comparator analysis with metformin.
01Findings
What the study reported
- Drugs
- Semaglutide, Liraglutide, Tirzepatide
- Comparator
- those receiving lifestyle interventions
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- obesity/overweight present (all or most)
- Diabetes status
- excluded (no diabetes)
Study quality details
- Study design
- Retrospective cohort
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- active comparator
- Follow up duration
- not stated
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI, 0
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- not available in metadata
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[BACKGROUND] Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists are increasingly used for adolescent obesity, but concerns persist regarding psychiatric adverse events, particularly suicidality. [METHODS] This retrospective cohort study used deidentified electronic health records from the TriNetX Global Collaborative Network. Adolescents with overweight or obesity were included. New users of semaglutide, liraglutide, or tirzepatide were compared with those receiving lifestyle interventions. Cohorts were balanced using propensity score matching. The primary outcome was suicide-related events (suicidal ideation or suicide attempt). Secondary outcomes included suicidal ideation, suicide attempt, anxiety, insomnia, depression, and eating disorders, assessed from 30 days to 1095 days after the index date. [RESULTS] After propensity score matching, 9222 adolescents were included in each group. Incretin-based therapy was associated with lower risks of suicide-related events (HR, 0.74; 95% CI, 0.57-0.95), suicidal ideation (HR, 0.73; 95% CI, 0.56-0.96), and anxiety (HR, 0.92; 95% CI, 0.84-0.99) compared with lifestyle intervention. No significant differences were observed for suicide attempt, insomnia, depression, or eating disorders. Risk reductions were significant among female adolescents (HR, 0.61; 95% CI, 0.46-0.82) and those without Type 2 diabetes (HR, 0.63; 95% CI, 0.47-0.85), but not among males or those with Type 2 diabetes. Sensitivity analyses supported the primary findings. [CONCLUSIONS] Among adolescents with obesity, incretin-based therapy was not associated with increased psychiatric risk and was associated with lower risks of suicide-related events, suicidal ideation, and anxiety compared with lifestyle intervention. Although a lower risk was observed compared with lifestyle intervention, this finding should be interpreted cautiously given potential selection bias and the lack of a significant difference in the active-comparator analysis with metformin.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 20, 2026 | 42736027 first ingestion |